Ab­b­Vie's Skyrizi takes home a win in late-stage Crohn's study, adding some heft to its ex­pan­sion plans

Ab­b­Vie hasn’t been shy about its block­buster am­bi­tions for pso­ri­a­sis med Skyrizi since launch, ar­gu­ing it could go a long way to stanch­ing the bleed­ing from Hu­mi­ra’s patent cliff. Now, the drug­mak­er is adding even more ar­mor to Skyrizi’s chances at Crohn’s dis­ease, a key in­di­ca­tion in the drug’s ex­pan­sion plans.

Ab­b­Vie’s Skyrizi dosed as a main­te­nance ther­a­py hit its pri­ma­ry end­points of clin­i­cal re­mis­sion and en­do­scop­ic re­sponse af­ter one year com­pared with an in­duc­tion phase of the drug fol­lowed by with­draw­al, ac­cord­ing to topline da­ta from the Phase III FOR­TI­FY study pre­sent­ed Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER